Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xiaojun Liu
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0000-0003-4432-6435
Observed ORCID:
0000-0003-4432-6435
OpenAlex ID:
A5133889675
Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer
2026
·
Jian Zhang
, Yiqun Du
, et al.
·
MedComm
·
2
Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial
2026
·
Xiaojun Liu
, Yanchun Meng
, et al.
·
The Oncologist
·
2
Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial
2026
·
Yanchun Meng
, Yingying Liu
, et al.
·
Journal of Clinical Oncology
·
1
Dexamethasone reduction or omission with NEPA and olanzapine for HEC: A phase III trial.
2026
·
Jian Zhang
, Yanchun Meng
, et al.
·
Journal of Clinical Oncology
Abstract CT289: Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid tumors
2026
·
Hongxia Wang
, Xiaohua Wu
, et al.
·
Cancer Research
Show more works
View as search
Works count:
5
Citation count:
5
H-index:
2
I10-index:
Year
Topic
Type